Harmony Biosciences Holdings (HRMY) — Capital Reinvestment Ratio
Latest as of December 2025:
0.00x
Harmony Biosciences Holdings (HRMY) has a Capital Reinvestment Ratio of 0.00x as of December 2025, meaning it reinvests 0% of its operating cash flow ($126.15 Million) in capital expenditures ($107.00K). See HRMY FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.00x
Capex / Operating Cash Flow
Operating Cash Flow
$126.15 Million
USD
Capital Expenditures
$107.00K
USD
Data as of
Dec 2025
Most recent filing
Harmony Biosciences Holdings Capital Reinvestment Ratio (2021–2025)
This chart tracks Harmony Biosciences Holdings's Capital Reinvestment Ratio across 5 annual periods.
Annual Capital Reinvestment Ratio for Harmony Biosciences Holdings (2021–2025)
Year-by-year Capital Reinvestment Ratio for Harmony Biosciences Holdings from 2021 to 2025. For live market cap and broader valuation context, see Harmony Biosciences Holdings market capitalisation.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.00x | $348.20 Million | $310.00K | ▼ -83.0% |
| 2024 | 0.01x | $219.82 Million | $1.15 Million | ▲ +268.8% |
| 2023 | 0.00x | $219.39 Million | $312.00K | ▲ +19.4% |
| 2022 | 0.00x | $144.47 Million | $172.00K | ▼ -60.6% |
| 2021 | 0.00x | $98.56 Million | $298.00K | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow